Barclays’s Ambit Biosciences Corp AMBI Stock Holding History

Barclays’s Portfolio AMBI Stock Details AMBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-1,300	Closed	-$12K	–	8026
2014 Q1	$12K	Sell	1,300 -2,757	-68%	-$29.3K	﹤0.01%	6866
2013 Q4	$37K	Buy	+4,057	New	+$54.2K	﹤0.01%	6393

Other funds holding AMBI

FCMI

Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return

Aisling Capital New York $45.3M AUM 15.24% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Barclays's AMBI Position: Q2 2014 in Review

Barclays sold out of Ambit Biosciences Corp (AMBI) in Q2 2014, closing a stake of 1,300 shares — an estimated $12K sold.

Barclays first reported a position in AMBI in Q4 2013 and held it in 2 quarters. The position peaked at $37K in Q4 2013. 36 funds tracked by Wall St. Rank hold AMBI as of Q2 2014.

Barclays reported no remaining Ambit Biosciences Corp position as of Q2 2014 after selling out during the quarter.
Barclays sold 1,300 Ambit Biosciences Corp shares in Q2 2014, an estimated $12K.
Barclays first reported a position in Ambit Biosciences Corp in Q4 2013 and held it in 2 quarters.
Barclays's Ambit Biosciences Corp position peaked at $37K in Q4 2013.
36 funds tracked by Wall St. Rank held Ambit Biosciences Corp as of Q2 2014.

Based on Barclays's 13F filing for Q2 2014, filed 14 Aug 2014.